The dollar amount is too small to signal any material change in business outlook. Monitor upcoming quarterly earnings for any fundamental shifts; these sales are routine and non-actionable.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $54.50entry
- T+1 · 6mo ago −1.17%α −1.76% · $53.86
- T+5 · 6mo ago +1.25%α −0.41% · $55.18
- T+20 · 5mo ago −1.83%α −0.42% · $53.50
- T+60 · 3mo ago +9.52%α +6.33% · $59.69
Price Chart
How similar events traded
Executive Summary
Two insiders at Royalty Pharma sold a combined $883K in open-market transactions over a one-week window. The sales represent ~0.003% of the $30.6B market cap, a trivial amount that is routine and non-informative. No material business catalyst is evident from the filing.
Key Financial Metrics
Key Facts
- Director Norden Gregory sold 3,000 shares at ~$53.00 for $161K on 2026-05-14.
- EVP Marshall Urist sold 13,684 shares at ~$52.75 for $722K on 2026-05-20.
- Total insider sales of $883K represent ~0.003% of RPRX's $30.6B market cap.
- No insider purchases were reported in the cluster window.
- Recent 30-day insider activity includes 4 prior sales totaling $3.2M, consistent with routine liquidity-driven selling.
Financial Impact
Total insider sales of $883K, or ~0.003% of market cap, economically negligible.
Risk Factors
- Insider sales could increase if the stock continues to appreciate, but no bearish signal is present here.
- No identifiable catalyst from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RPRX-1779412846308 |
Track record
23 reports on RPRX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers